Madrigal shares soar on promising PhII NASH data, stoking hopes for a new contender

You can add Madrigal Pharmaceuticals $MDGL to your list of NASH contenders — and a soaring share price this morning to underscore the blockbuster market it’s aiming at.

The key endpoints reported this morning center on the resolution of NASH, with 56% of the patients in the MGL-3196 group seeing a greater than two point reduction in their NAS score, compared to 32% in the placebo arm after 36 weeks. And among the 12-week responders the score was higher, at 70%.

Paul Friedman, CEO

NASH resolution was achieved in 27% of the drug arm and 39% of the early responders — clearly upbeat results for the biotech. In the placebo group, only 6% achieved NASH resolution.

Madrigal’s move into the NASH spotlight this morning was richly rewarded with a greater than 60% increase in their share price, what you might call a key unspecified primary endpoint not written into the protocol.

Rising obesity rates has made NASH a darling in the drug development crowd. Madrigal still has a long way to go, and it will get a closer inspection now at every turn of the process.

The principal investigator, Stephen Harrison, boasted:

Compared with Week 12, at Week 36 MGL-3196 showed sustained effects to reduce liver fat on MRI-PDFF, and more reduction in liver enzymes than placebo. MGL-3196 demonstrates improvement relative to placebo on measurements of NASH on liver biopsy, including resolution of NASH. Importantly, this study is the first to demonstrate a correlation between efficacy in a non-invasive imaging test, MRI-PDFF at 12 weeks, and improvement in NASH on liver biopsy at 36 weeks.

Image: Liver Shutterstock

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco
Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC

Visit Endpoints Careers ->